NeuralStem Inc.
387 Technology Drive
College Park
Maryland
20742
United States
Tel: 301-314-2671
Fax: 301-405-1064
Email: aformal@neuralstem.com
246 articles about NeuralStem Inc.
-
Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit
10/29/2019
Seneca Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit to be held at the Pudong Shangri-La Hotel in East Shanghai on October 31 – November 1.
-
Neuralstem Becomes Seneca Biopharma
10/28/2019
-
Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)
10/3/2019
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced the adjustment of an options award that was previously approved in accordance with Nasdaq Listing Rule 5635(c)(4).
-
Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients
9/24/2019
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced completion of subject enrollment in its Phase 2 clinical trial of NSI-566 for the treatment of chronic ischemic stroke
-
Neuralstem Reports Second Quarter 2019 Fiscal Results
8/14/2019
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, reported its financial results for the second quarter ended June 30, 2019.
-
Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing
8/7/2019
Nasdaq has granted the Company's request for continued listing of the Company's stock on the Nasdaq Stock Market.
-
Neuralstem Closes $7.5 Million Underwritten Public Offering
7/31/2019
Neuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the "Company") today announced the closing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit resulting in gross proceeds of approximately $7,500,000, before deducting discount, commissions and estimated offering expenses.
-
Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering - July 25, 2019
7/26/2019
Neuralstem, Inc. announced the pricing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit for gross proceeds of approximately $7,500,000, before deducting discount and commissions and estimated offering expenses.
-
Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors
7/18/2019
Neuralstem, Inc. announced that Mary Ann Gray, Ph.D. has been appointed to the Company's Board of Directors.
-
Neuralstem Announces a 1-for-20 Reverse Stock Split
7/16/2019
The reverse stock split will become effective on Wednesday, July 17, 2019 after market close and shares of Neuralstem Inc. common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "CUR," at the market open on Thursday, July 18, 2019.
-
Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients
7/1/2019
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the publication of a manuscript in Stem Cells Translational Medicine describing the results of an open label Phase 1 clinical trial evaluating the feasibility and safety of transplantation of its lead stem cell asset, NSI-566, for the treatment of motor deficits due to ischemic stroke.
-
Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells
5/16/2019
Neuralstem, Inc. announced the expansion of their intellectual property portfolio with the recent issuance of a newly published patent.
-
Neuralstem Reports First Quarter 2019 Fiscal Results
5/14/2019
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, reported its financial results for the first quarter ended March 31, 2019.
-
Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors
5/6/2019
Neuralstem, Inc. announced that David J. Mazzo, Ph.D. has been appointed to the Company's Board of Directors to be effective June 12, 2019.
-
Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort
2/7/2019
Neuralstem Engages Strategic Advisors to Evaluate Dozens of New Technologies
-
Neuralstem Announces Publication of a Study Showing Benefits of Neural Stem Cell (NSC) Transplantation in a Mouse Model of Alzheimer’s Disease
10/25/2018
NSC transplantation led to improved cognition and reduced Aβ plaque pathology
-
Neuralstem Appoints Jim Scully as Interim Chief Executive Officer
8/6/2018
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, today announced that the Board of Directors has appointed Jim Scully as interim chief executive officer.
-
New Member Appointed to the Board of Directors of Neuralstem
12/20/2017
Dr. Chen was appointed by Tianjin to replace Zhang Zhuo as the director appointee of the Series A Convertible Preferred Stock.
-
Neuralstem Presents Positive Updated Data from Phase II Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting
12/5/2017
These additional results suggest that NSI-189 has antidepressant effects with cognitive benefits shown on both objective and subjective measures.
-
Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update
11/13/2017
At September 30, 2017, cash and investments was $14.1 million as compared to $11.4 million at June 30, 2017.